Therapeutic Area | MeSH |
---|---|
respiratory tract diseases | D012140 |
cardiovascular diseases | D002318 |
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
LETAIRIS | Gilead Sciences | N-022081 RX | 2007-06-15 | 2 products, RLD, RS |
Brand Name | Status | Last Update |
---|---|---|
ambrisentan | ANDA | 2024-12-05 |
letairis | New Drug Application | 2025-02-12 |
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
pulmonary hypertension | EFO_0001361 | D006976 | I27.20 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | 2 | 4 | 4 | — | 2 | 12 |
Hypertension | D006973 | EFO_0000537 | I10 | 1 | 4 | 5 | — | 1 | 11 |
Pulmonary arterial hypertension | D000081029 | — | — | — | 4 | 3 | — | 1 | 8 |
Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 1 | — | — | 1 |
Familial primary pulmonary hypertension | D065627 | — | I27.0 | — | — | 1 | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Systemic scleroderma | D012595 | EFO_0000717 | M34 | — | 1 | — | — | — | 1 |
Diffuse scleroderma | D045743 | EFO_0000404 | — | — | 1 | — | — | — | 1 |
Sclerosis | D012598 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Drug common name | Ambrisentan |
INN | ambrisentan |
Description | Ambrisentan is a diarylmethane. |
Classification | Small molecule |
Drug class | endothelin receptor antagonists |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | COC(c1ccccc1)(c1ccccc1)[C@H](Oc1nc(C)cc(C)n1)C(=O)O |
PDB | — |
CAS-ID | 177036-94-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1111 |
ChEBI ID | — |
PubChem CID | 6918493 |
DrugBank | DB06403 |
UNII ID | HW6NV07QEC (ChemIDplus, GSRS) |